Table 1.

Studies estimating the total cost burden of DLBCL.

Study	Location	Intervention of interest	Indication	Mean total cost (2019 USD)	Conclusion
Wang, et al. [33]	United Kingdom	Total treatment pathway	DLBCL	Per-patient: $31,499	Considerable variability with range $5,017 (palliative care alone) to $135,493 (patients receiving autologous HCT)
Morrison, et al. [34]	USA	Total treatment pathway	DLBCL	PPPM: $12,804	Significant cost burden, particularly in the first year after DLBCL diagnosis
Ren, et al. [35]	USA	Total treatment pathway	DLBCL	PPPM: $16,751	Considerable healthcare costs and resource utilization
Costa, et al. [36]	Canada	Total treatment pathway	DLBCL	Per-patient: first 6 months following diagnosis, $25,743; first 6 months following relapse, $16,337	Greatest cost observed in first 6 months after diagnosis or disease progression with significant drop in cost in subsequent time intervals

Abbreviations: DLBCL, diffuse large B-cell lymphoma; HCT, hematopoietic cell transplant; ICER, incremental cost-effectiveness ratio; PPPM, per-patient-per-month; USD, US dollars